Top

Published in:

13-09-2023 | Melanoma | Original Paper

Effects of treatment methods on cutaneous melanoma related mortality and all-cause mortality in Texas: TCR-Medicare 2007–2017 database

Authors: Fabiola Ramirez, Hannah Riva, Biai Digbeu, Michelle Samaniego, Lorena Fernandez, Sara Mansour, Rebecca Vasquez, David S. Lopez, Jessica Chacon

Published in: Cancer Causes & Control | Issue 2/2024

Abstract

Purpose

The incidence of cutaneous melanoma is rising, and Melanoma related deaths are highest among people aged 65–74. Herein, we aim to understand the impact of novel and established melanoma treatment methods on CM related mortality and all-cause mortality. We further compared these effects among Hispanic and non-Hispanic Whites (NHW).

Methods

The data was extracted from the Texas Cancer Registry from 2007 to 2017. A Cox Proportional Hazard regression analysis was performed to assess treatment effect on melanoma mortality and all-cause mortality, with race-ethnicity as an effect modifier.

Results

A higher percentage of Hispanic patients presented with CM-related mortality (22.11%) compared to NHW patients (14.39%). In both the Hispanic and NHW, post-diagnosis radiation (HR = 1.610, 95% CI 0.984–2.634, HR = 2.348, 95% CI 2.082–2.648, respectively), post-diagnosis chemotherapy (HR = 1.899, 95% CI 1.085–3.322, HR = 2.035, 95% CI 1.664–2.489, respectively), and post-diagnosis immunotherapy (HR = 2.100, 95% CI 1.338–3.296, HR = 2.402, 95% CI 2.100–2.748) are each associated with an increased risk in CM-related mortality. Similar results were seen with post-diagnosis radiation (Hispanic HR = 1.640, 95% CI 1.121–2.400, NHW HR = 1.800, 95% CI 1.644–1.971), post-diagnostic chemotherapy (Hispanic HR = 1.457, 95% CI 0.898–2.364, NHW HR = 1.592, 95% CI 1.356–1.869), and post-diagnosis immunotherapy (Hispanic HR = 2.140, 95% CI 1.494–3.065, NHW HR = 2.190, 95% CI 1.969–2.435) with respect to all-cause mortality. Post-diagnosis surgery (HR = 0.581, 95% CI 0.395–0.856, HR = 0.622, 95% CI 0.571–0.678) had the opposite effect in CM-related mortality for Hispanics and NHWs respectively.

Conclusion

Our results propose differences in all-cause and CM-only related mortality with separate treatment modalities, particularly with chemotherapy, radiation therapy and immunotherapy. In addition, this retrospective cohort study showed that health disparities exist in the Hispanic Medicare population of Texas with CM.

Available only for authorised users

Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC (2015) Vital signs: melanoma incidence and mortality trends and projections - United States, 1982–2030, (in eng). MMWR Morb Mortal Wkly Rep 64(21):591–596PubMedPubMedCentral

Leiter U, Keim U, Garbe C (2020) Epidemiology of skin cancer: update 2019, (in eng). Adv Exp Med Biol 1268:123–139. https://doi.org/10.1007/978-3-030-46227-7_6CrossRefPubMed

Cormier JN et al (2006) Ethnic differences among patients with cutaneous melanoma, (in eng). Arch Intern Med 166(17):1907–1914. https://doi.org/10.1001/archinte.166.17.1907CrossRefPubMed

Ward-Peterson M et al (2016) Association between race/ethnicity and survival of melanoma patients in the United States over 3 decades a secondary analysis of SEER Data. Medicine 95(17):e3315. https://doi.org/10.1097/md.0000000000003315CrossRefPubMedPubMedCentral

Garnett E, Townsend J, Steele B, Watson M (2016) Characteristics, rates, and trends of melanoma incidence among Hispanics in the USA, (in eng). Cancer Causes Control 27(5):647–659. https://doi.org/10.1007/s10552-016-0738-1CrossRefPubMedPubMedCentral

Qian Y, Johannet P, Sawyers A, Yu J, Osman I, Zhong J (2021) The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975–2016), (in eng). J Am Acad Dermatol 84(6):1585–1593. https://doi.org/10.1016/j.jaad.2020.08.097CrossRefPubMed

Sanchez DP et al (2020) Racial and ethnic disparities in melanoma awareness: A cross-sectional survey, (in eng). J Am Acad Dermatol 83(4):1098–1103. https://doi.org/10.1016/j.jaad.2020.04.137CrossRefPubMed

healthinsurance.org. "Health insurance coverage options in Texas | healthinsurance.org." https://www.healthinsurance.org/states/texas/ (accessed 2022).

Xie L, Kariburyo MF, Du J, Baser O (2014) Assessing the economic burden and health care utilization of U. S. medicare patients diagnosed with melanoma (in eng). Value Health 17(7):A625. https://doi.org/10.1016/j.jval.2014.08.2225CrossRefPubMed

10.

"Melanoma skin cancer statistics." https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html#:~:text=The%20average%20age%20of%20people,adults%20(especially%20young%20women). (accessed 9 Sep, 2023).

11.

Gogebakan KC, Mukherjee K, Berry EG, Sonmez K, Leachman SA, Etzioni R (2021) Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries, (in eng). Cancer 127(16):2926–2933. https://doi.org/10.1002/cncr.33515CrossRefPubMed

12.

Seiger K, Schmults CD, Silk AW, Ruiz ES (2020) Cost and utilization of immunotherapy and targeted therapy for melanoma: Cross-sectional analysis in the Medicare population, 2013 and 2015, (in eng). J Am Acad Dermatol 82(3):761–764. https://doi.org/10.1016/j.jaad.2019.10.023CrossRefPubMed

13.

Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL Jr, Anton-Culver H (2008) Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment, (in eng). J Clin Oncol 26(1):66–75. https://doi.org/10.1200/jco.2007.12.3604CrossRefPubMed

14.

Merrill RM, Pace ND, Elison AN (2010) Cutaneous malignant melanoma among white Hispanics and non-Hispanics in the United States (in eng). Ethn Dis 20(4):353–8PubMed

15.

Wang Y, Zhao Y, Ma S (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology (in eng). BMC Cancer 16(1):691. https://doi.org/10.1186/s12885-016-2747-6CrossRefPubMedPubMedCentral

16.

Perez MI (2019) Skin Cancer in Hispanics in the United States, (in eng). J Drugs Dermatol 18(3):s117-120PubMed

17.

Trofymenko O, Bordeaux JS, Zeitouni NC (2018) Melanoma of the Face and Mohs Micrographic Surgery: Nationwide Mortality Data Analysis, (in eng). Dermatol Surg 44(4):481–492. https://doi.org/10.1097/dss.0000000000001429CrossRefPubMed

18.

Hartman RI, Lin JY (2019) Cutaneous Melanoma-A Review in Detection, Staging, and Management, (in eng). Hematol Oncol Clin North Am 33(1):25–38. https://doi.org/10.1016/j.hoc.2018.09.005CrossRefPubMed

19.

J. A. Sosman. "Overview of the management of advanced cutaneous melanoma - UpToDate." UpToDate. https://www-uptodate-com.libraryaccess.elpaso.ttuhsc.edu/contents/overview-of-the-management-of-advanced-cutaneous-melanoma?search=melanoma&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3 (accessed June 2022, 2022).

20.

Rozeman EA, Dekker TJA, Haanen J, Blank CU (2018) Advanced melanoma: current treatment options, biomarkers, and future perspectives, (in eng). Am J Clin Dermatol 19(3):303–317. https://doi.org/10.1007/s40257-017-0325-6CrossRefPubMed

21.

Mishra H, Mishra PK, Ekielski A, Jaggi M, Iqbal Z, Talegaonkar S (2018) Melanoma treatment: from conventional to nanotechnology, (in eng). J Cancer Res Clin Oncol 144(12):2283–2302. https://doi.org/10.1007/s00432-018-2726-1CrossRefPubMed

22.

Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview, (in eng). Oncology (Williston Park) 23(6):488–496PubMed

23.

Sankey EW et al (2019) Operative and peri-operative considerations in the management of brain metastasis, (in eng). Cancer Med 8(16):6809–6831. https://doi.org/10.1002/cam4.2577CrossRefPubMedPubMedCentral

24.

TCR. Cancer Statistics. https://www.dshs.texas.gov/tcr/data/statistics.aspx (accessed.

25.

Shah BR, Hux JE, Laupacis A, Zinman B, Cauch-Dudek K, Booth GL (2007) Administrative data algorithms can describe ambulatory physician utilization, (in eng). Health Serv Res 42(4):1783–1796. https://doi.org/10.1111/j.1475-6773.2006.00681.xCrossRefPubMedPubMedCentral

26.

Quan H et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, (in eng). Med Care 43(11):1130–1139. https://doi.org/10.1097/01.mlr.0000182534.19832.83CrossRefPubMed

27.

R. S. Young JL Jr, Ries LAG, Fritz AG,Hurlbut AA, 2001 SEER Summary Staging Manual - 2000: Codes and Coding Instructions, NIH Pub. No. 01-4969

28.

Hu S et al (2009) Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida, (in eng). Arch Dermatol 145(12):1369–1374. https://doi.org/10.1001/archdermatol.2009.302CrossRefPubMed

29.

Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY (2008) Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis, (in eng). Lancet Oncol 9(3):222–231. https://doi.org/10.1016/s1470-2045(08)70032-9CrossRefPubMed

30.

Miller DR et al (1996) Melanoma awareness and self-examination practices: results of a United States survey, (in eng). J Am Acad Dermatol 34(6):962–970. https://doi.org/10.1016/s0190-9622(96)90273-xCrossRefPubMed

31.

Chao LX, Patterson SSL, Rademaker AW, Liu D, Kundu RV (2017) Melanoma perception in people of color: a targeted educational intervention, (in eng). Am J Clin Dermatol 18(3):419–427. https://doi.org/10.1007/s40257-016-0244-yCrossRefPubMed

32.

Ortiz CA, Goodwin JS, Freeman JL (2005) The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma, (in eng). Med Sci Monit 11(5):163–172

33.

Falcon K, Fors M, Palacios Alvarez S, Veintimilla K, Lasso N, Navas C (2019) Assessment of predictors of sun sensitivity as defined by fitzpatrick skin phototype in an ecuadorian population and its correlation with skin damage, (in eng). Dermatology 235(5):400–406. https://doi.org/10.1159/000500635CrossRefPubMed

34.

Velasco-Mondragon E, Jimenez A, Palladino-Davis AG, Davis D, Escamilla-Cejudo JA (2016) Hispanic health in the USA: a scoping review of the literature, (in eng). Public Health Rev 37:31. https://doi.org/10.1186/s40985-016-0043-2CrossRefPubMedPubMedCentral

35.

Dominguez K et al (2015) Vital signs: leading causes of death, prevalence of diseases and risk factors, and use of health services among Hispanics in the United States - 2009–2013, (in eng). MMWR Morb Mortal Wkly Rep 64(17):469–478PubMedPubMedCentral

36.

Eriksson H et al (2013) Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden, (in eng). Eur J Cancer 49(12):2705–2716. https://doi.org/10.1016/j.ejca.2013.03.013CrossRefPubMed

37.

Coups EJ, Geller AC, Weinstock MA, Heckman CJ, Manne SL (2010) Prevalence and correlates of skin cancer screening among middle-aged and older white adults in the United States, (in eng). Am J Med 123(5):439–445. https://doi.org/10.1016/j.amjmed.2009.10.014CrossRefPubMedPubMedCentral

38.

Vaidya T, Zubritsky L, Alikhan A, Housholder A (2018) Socioeconomic and geographic barriers to dermatology care in urban and rural US populations, (in eng). J Am Acad Dermatol 78(2):406–408. https://doi.org/10.1016/j.jaad.2017.07.050CrossRefPubMed

39.

Coups EJ, Stapleton JL, Hudson SV, Medina-Forrester A, Goydos JS, Natale-Pereira A (2012) Skin cancer screening among Hispanic adults in the United States: results from the 2010 National Health Interview Survey. In Arch Dermatol 148(7):861–3CrossRef

40.

Brown AE, Najmi M, Duke T, Grabell DA, Koshelev MV, Nelson KC (2022) Skin cancer education interventions for primary care providers: a scoping review, (in eng). J Gen Intern Med 37(9):2267–2279. https://doi.org/10.1007/s11606-022-07501-9CrossRefPubMedPubMedCentral

41.

Haque W, Verma V, Butler EB, Teh BS (2019) Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States, (in eng). J Immunother 42(6):228–235. https://doi.org/10.1097/cji.0000000000000264CrossRefPubMed

42.

Molina G, Kasumova GG, Qadan M, Boland GM (2020) Use of immunotherapy and surgery for stage IV melanoma, (in eng). Cancer 126(11):2614–2624. https://doi.org/10.1002/cncr.32817CrossRefPubMed

43.

Al-Qurayshi Z, Crowther JE, Hamner JB, Ducoin C, Killackey MT, Kandil E (2018) Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective, (in eng). Anticancer Res 38(5):2897–2901. https://doi.org/10.21873/anticanres.12536CrossRefPubMed

44.

Moyers JT, Patel A, Shih W, Nagaraj G (2020) Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US, (in eng). JAMA Netw Open 3(9):e2015656. https://doi.org/10.1001/jamanetworkopen.2020.15656CrossRefPubMedPubMedCentral

45.

Ikeguchi A, Machiorlatti M, Vesely SK (2020) Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile (in eng). Melanoma Manag 7(2):Mmt43. https://doi.org/10.2217/mmt-2020-0002CrossRefPubMedPubMedCentral

46.

Dranitsaris G, Zhu X, Adunlin G, Vincent MD (2018) Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs (in eng). Expert Rev Pharmacoecon Outcomes Res 18(4):351–357. https://doi.org/10.1080/14737167.2018.1467270CrossRefPubMed

47.

Shaw DL, Dhruva SS, Ross JS (2018) coverage of novel therapeutic agents by medicare prescription drug plans following FDA approval, (in eng). J Manag Care Spec Pharm 24(12):1230–1238. https://doi.org/10.18553/jmcp.2018.24.12.1230CrossRefPubMed

48.

Singh SRK, Malapati SJ, Kumar R, Willner C, Wang D (2021) NCDB Analysis of melanoma 2004–2015: epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and real-world survival benefit of immunotherapy approval (in eng). Cancers (Basel). https://doi.org/10.3390/cancers13061455CrossRefPubMedPubMedCentral

49.

Mangin MA et al (2021) Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma, (in eng). Cancer Med 10(10):3155–3164. https://doi.org/10.1002/cam4.3760CrossRefPubMedPubMedCentral

Title: Effects of treatment methods on cutaneous melanoma related mortality and all-cause mortality in Texas: TCR-Medicare 2007–2017 database
Authors: Fabiola Ramirez
Hannah Riva
Biai Digbeu
Michelle Samaniego
Lorena Fernandez
Sara Mansour
Rebecca Vasquez
David S. Lopez
Jessica Chacon
Publication date: 13-09-2023
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Cytostatic Therapy
Published in: Cancer Causes & Control / Issue 2/2024
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-023-01780-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Household cooking fuel and gallbladder cancer risk: a multi-centre case–control study in India

Untargeted serum metabolomic profiles and breast density in young women

Factors associated with adherence to medications for lowering breast cancer risk between female Medicare beneficiaries in Alabama and nationwide

Socioeconomic and geographic disparities of breast cancer incidence according to stage at diagnosis in France

Lifetime alcohol consumption patterns and young-onset breast cancer by subtype among Non-Hispanic Black and White women in the Young Women’s Health History Study

Estimating uninsured and underinsured women eligible for Minnesota’s Breast Cancer Screening Program

Keynote webinar | Spotlight on antibody–drug conjugates in cancer